Melbourne medicinal cannabis company debuts on the ASX with $19.65m IPO

Melbourne medicinal cannabis company debuts on the ASX with $19.65m IPO

There's certainly no shortage of medicinal cannabis stocks to invest in on the ASX, and with today's listing of Althea (ASX: AGH) we're certainly spoilt for choice.

The Melbourne-based medicinal cannabis company launched on the ASX on Friday morning after a hugely successful and heavily oversubscribed IPO of $19.65 million.

Althea, which specialises in importing, cultivating, producing and supplying medicinal cannabis for eligible patients across Australia issued 98.25 million new shares at $0.20 per share during the IPO, giving the company a market cap of $40.6 million on listing.

Althea has been supplying patients in Australia since May, making it the first Aussie company to do so.

Thanks to its strategic partnership with Canadian giant Aphira, Althea commenced importing and supplying five Althea branded medicinal products to eligible patients in cannabis oil and dried flower form back in May.

Aphira, one of the largest medicinal cannabis companies listed on the Toronto Stock Exchange, took a cornerstone position in the IPO, and now holds 25 per cent in Althea.

CEO and MD of Althea, Joshua Fegan, says the company is hyper-focused on patients outcomes.

"Our aim is to educate and support patient access to medicinal cannabis in Australia," says Fegan.

"Our measured three-stage growth plan supports Althea's vision to become a leading and trusted medicinal cannabis brand in Australia."

READ: The Cannabis Index: A complete guide to cannabis stocks on the ASX

Althea's three-stage business model involves early revenue generation, sales driven growth, and scalable domestic production.

The company has even engaged a team of medical science liaisons who are working to assist medical practitioners to become prescribers, and pharmacists to become suppliers, of Althea products.

The company will put the $19.65 million raised in the IPO toward brand awareness initiatives, and fund the design, construction, and commissioning and completion of a 4,080sqm medicinal cannabis cultivation, extraction and manufacturing facility in Skye, Victoria. The facility is expected to product approximately 3 tonnes of cannabis each year.

"Looking ahead, we intend to double down on our medical education program and leverage technology to build a greater understanding of medicinal cannabis for patients and healthcare professionals through Althea Concierge, our web-based platform and free-to-download mobile app," says Fegan.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Interest rates: To fix or not to fix?
Partner Content
Interest rates are on the move as evidenced by another rise issued by the Reserve Bank ...
WMS
Advertisement

Related Stories

Adore Beauty CEO Tennealle O’Shannessy tenders resignation

Adore Beauty CEO Tennealle O’Shannessy tenders resignation

Online cosmetics retailer Adore Beauty (ASX: ABY) CEO Tennealle O&r...

GIC acquires half-stake in Charter Hall’s $1.5 billion 555 Collins Street tower

GIC acquires half-stake in Charter Hall’s $1.5 billion 555 Collins Street tower

Leading property investment management company Charter Hall has sol...

Flora & Fauna founder Julie Mathers acquires babywear brand Snuggle Hunny Kids

Flora & Fauna founder Julie Mathers acquires babywear brand Snuggle Hunny Kids

Julie Mathers, who sold her online retail business Flora & Faun...

Mesoblast shares slide on $65m capital raise announcement

Mesoblast shares slide on $65m capital raise announcement

Shares in Australian biotech Mesoblast (ASX: MSB) have fallen by 7 ...